Henrik Agersø

3.6k total citations · 1 hit paper
52 papers, 2.8k citations indexed

About

Henrik Agersø is a scholar working on Endocrinology, Diabetes and Metabolism, Hematology and Molecular Biology. According to data from OpenAlex, Henrik Agersø has authored 52 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Henrik Agersø's work include Hemophilia Treatment and Research (15 papers), Blood Coagulation and Thrombosis Mechanisms (13 papers) and Growth Hormone and Insulin-like Growth Factors (9 papers). Henrik Agersø is often cited by papers focused on Hemophilia Treatment and Research (15 papers), Blood Coagulation and Thrombosis Mechanisms (13 papers) and Growth Hormone and Insulin-like Growth Factors (9 papers). Henrik Agersø collaborates with scholars based in Denmark, Sweden and United States. Henrik Agersø's co-authors include Milan Zdravković, Paul Rolan, Jens J. Holst, Tina Vilsbøll, Thure Krarup, Lene Jensen, Michael Wilken, Per F. Nielsen, Per Olaf Huusfeldt and Nils L. Johansen and has published in prestigious journals such as Blood, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Henrik Agersø

52 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

2000 579 citations Henrik Agersø et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henrik Agersø Denmark	23	1.8k	1.1k	987	379	294	52	2.8k
Charles Benson United States	23	1.7k 0.9×	1.4k 1.2×	695 0.7×	691 1.8×	275 0.9×	55	3.2k
Anne Hermanowski‐Vosatka United States	27	901 0.5×	1.2k 1.1×	628 0.6×	318 0.8×	106 0.4×	38	3.4k
Kenneth Mace United States	23	1.0k 0.6×	461 0.4×	635 0.6×	219 0.6×	76 0.3×	35	1.7k
Kevin Godbout United States	6	1.2k 0.7×	809 0.7×	381 0.4×	736 1.9×	212 0.7×	7	3.6k
Michael Gosselin United States	6	849 0.5×	681 0.6×	412 0.4×	370 1.0×	94 0.3×	9	3.2k
Nathalie Pamir United States	21	829 0.5×	697 0.6×	684 0.7×	61 0.2×	218 0.7×	37	1.9k
Paul Hales United States	15	539 0.3×	957 0.8×	234 0.2×	425 1.1×	149 0.5×	22	2.2k
David W. Garber United States	29	1.2k 0.7×	1.2k 1.0×	1.7k 1.8×	96 0.3×	79 0.3×	51	3.3k
Jun Saito Japan	28	1.5k 0.8×	716 0.6×	1000 1.0×	48 0.1×	81 0.3×	124	2.6k
Chris Tikellis Australia	27	622 0.3×	763 0.7×	287 0.3×	243 0.6×	66 0.2×	41	2.5k

Countries citing papers authored by Henrik Agersø

Since Specialization

Citations

This map shows the geographic impact of Henrik Agersø's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Agersø with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Agersø more than expected).

Fields of papers citing papers by Henrik Agersø

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Agersø. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Agersø. The network helps show where Henrik Agersø may publish in the future.

Co-authorship network of co-authors of Henrik Agersø

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Agersø. A scholar is included among the top collaborators of Henrik Agersø based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Agersø. Henrik Agersø is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Almholt, Kasper, Jesper Pass, Gustav Røder, et al.. (2020). Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis. Journal of Molecular Medicine. 98(4). 585–593. 1 indexed citations

Groth, Andreas, et al.. (2018). Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia. European Journal of Pharmaceutical Sciences. 115. 196–203. 3 indexed citations

Thygesen, Peter, et al.. (2016). The kidneys play a central role in the clearance of rhGH in rats. European Journal of Pharmaceutical Sciences. 86. 29–33. 6 indexed citations

Agersø, Henrik, Rune Viig Overgaard, Lene Hansen, et al.. (2014). Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. European Journal of Pharmaceutical Sciences. 56. 65–69. 33 indexed citations

Agersø, Henrik & Mikael Tranholm. (2012). Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. Haemophilia. 18(s5). 6–10. 5 indexed citations

Brophy, Donald F., Erika G. Martin, John C. Barrett, et al.. (2011). Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h. Haemophilia. 17(5). e949–57. 8 indexed citations

Karpf, Ditte M., Marianne Kjalke, L. Thim, et al.. (2011). Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia. 17(5). e963–8. 12 indexed citations

Kristensen, Annemarie T., Henrik Agersø, A. L. Jensen, et al.. (2011). Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog. Haemophilia. 17(6). 962–970. 9 indexed citations

Petersen, Lars C., Ditte M. Karpf, Henrik Agersø, et al.. (2010). Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. British Journal of Haematology. 152(1). 99–107. 15 indexed citations

10.

Jadhav, Pravin, Henrik Agersø, Christoffer W. Tornøe, & Jogarao Gobburu. (2006). Semi-Mechanistic Pharmacodynamic Modeling for Degarelix, a Novel Gonadotropin Releasing Hormone (GnRH) Blocker. Journal of Pharmacokinetics and Pharmacodynamics. 33(5). 609–634. 16 indexed citations

11.

Tornøe, Christoffer W., Rune Viig Overgaard, Henrik Agersø, et al.. (2005). Stochastic Differential Equations in NONMEM®: Implementation, Application, and Comparison with Ordinary Differential Equations. Pharmaceutical Research. 22(8). 1247–1258. 50 indexed citations

12.

Agersø, Henrik, et al.. (2004). Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. British Journal of Clinical Pharmacology. 58(4). 352–358. 58 indexed citations

13.

Tornøe, Christoffer W., Henrik Agersø, Henrik Aalborg Nielsen, Henrik Madsen, & E. Niclas Jonsson. (2004). Population Pharmacokinetic Modeling of a Subcutaneous Depot for GnRH Antagonist Degarelix. Pharmaceutical Research. 21(4). 574–584. 27 indexed citations

14.

Tornøe, Christoffer W., Henrik Agersø, E. Niclas Jonsson, Henrik Madsen, & Henrik Aalborg Nielsen. (2004). Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations. Computer Methods and Programs in Biomedicine. 76(1). 31–40. 36 indexed citations

15.

Agersø, Henrik, et al.. (2003). The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. European Journal of Pharmaceutical Sciences. 20(3). 335–340. 14 indexed citations

16.

Agersø, Henrik & Paolo Vicini. (2003). Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. European Journal of Pharmaceutical Sciences. 19(2-3). 141–150. 55 indexed citations

17.

Agersø, Henrik, et al.. (2002). Pharmacokinetics and Pharmacodynamics of a New Formulation of Recombinant Human Growth Hormone Administered by ZomaJet 2 Vision, a New Needle‐Free Device, Compared to Subcutaneous Administration Using a Conventional Syringe. The Journal of Clinical Pharmacology. 42(11). 1262–1268. 28 indexed citations

18.

Zdravković, Milan, Birgitte Søgaard, Lars Ynddal, et al.. (2000). The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Hormone & IGF Research. 10(4). 193–198. 13 indexed citations

19.

Agersø, Henrik, Christian Friis, & Jens Peter Nielsen. (1998). Penetration of amoxycillin to the respiratory tract tissues and secretions in Actinobacillus pleuropneumoniae infected pigs. Research in Veterinary Science. 64(3). 251–257. 27 indexed citations

20.

Agersø, Henrik & Christian Friis. (1998). Penetration of amoxycillin into the respiratory tract tissues and secretions in pigs. Research in Veterinary Science. 64(3). 245–250. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact